RespireRx Pharmaceuticals Inc.
RSPI · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $295 | $252 | $535 | $289 |
| - Cash | $6 | $7 | $0 | $0 |
| + Debt | $2,781 | $2,873 | $2,854 | $2,709 |
| Enterprise Value | $3,069 | $3,118 | $3,389 | $2,997 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$77 | $10 | -$335 | $1 |
| % Margin | – | – | – | – |
| Net Income | -$396 | -$681 | -$430 | -$317 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.002 | -0.004 | -0.003 | -0.003 |
| % Growth | 62.5% | -29% | -24% | – |
| Operating Cash Flow | -$101 | -$129 | -$29 | $11 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$101 | -$129 | -$29 | $11 |